WHO & Regional Offices [to 16 Feb 2019]
 
12 February 2019
News Release
New WHO-ITU standard aims to prevent hearing loss among 1.1 billion young people
 
12 February 2019
News Release
International push to improve food safety
 
11 February 2019 | News release
US$ 43.5 million needed to provide life-saving health aid in Libya in 2019
 
::::::
  
Weekly Epidemiological Record, 15 February 2019, vol. 94, 07 (pp. 81–84)
:: 7th Meeting of the WHO Expert Working Group of the Global Influenza Surveillance and Response System for Surveillance of Antiviral Susceptibility
:: Executive summary of the 10th meeting of the WHO Working Group for the Molecular :: Detection and Subtyping of Influenza Viruses and the use of next-generation sequencing in the Global Influenza Surveillance and Response System
 
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Cabo Verde is ready to host 2nd African Health Forum and share good practices on progress towards Universal Health Coverage  14 February 2019
:: Uganda Health Workers Respond Swiftly to a Suspected Ebola Death  12 February 2019
:: Ethiopia Launches Measles Vaccine Second Dose (MCV2) Introduction: Over 3.3 million children will receive the vaccine annually  11 February 2019
:: Nigeria’s call to action – Time to Eliminate Cervical Cancer in Nigeria  10 February 2019
 
 
WHO Region of the Americas PAHO
:: Latest PAHO “Basic Indicators” shed light on health situation in the Americas (02/13/2019)

Vaccination
Vaccination coverage in 2017 varies for different vaccines: 94% percent of the target population of children in the Americas received the tuberculosis (BCG) vaccine; 90% received the vaccine for the first dose of measles, mumps, and rubella (MMR1); 88% received three doses of diphtheria, tetanus and pertussis (DTP3) vaccine; 85% received three doses of polio vaccine; and 73% received the last dose of rotavirus vaccine.
 
WHO South-East Asia Region SEARO
– No new digest announcements identified.
 
WHO European Region EURO
:: Towards a digital health roadmap for the WHO European Region 14-02-2019
 
 
WHO Eastern Mediterranean Region EMRO
:: Effective collaboration mitigates risk of potential outbreak
13 February 2019 – Intercountry collaboration between Iraq and Jordan allowed WHO and health authorities in Iraq to rapidly and successfully respond to an increase in cases of acute respiratory infections.
The last week of November 2018 witnessed an alarming rise in the incidence of acute respiratory infections in Suleimaniya governorate in the Kurdistan Region of Iraq. By 31 December, more than 35 suspected cases of influenza were admitted to Shaheed Hemin Hospital for Internal Medicine in the governorate…
:: US$ 43.5 million needed to provide life-saving health aid in Libya  11 February 2019
 
 
WHO Western Pacific Region
– No new digest announcements identified.

CDC/ACIP [to 16 Feb 2019]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for February 15, 2019
Update: Influenza Activity — United States, September 30, 2018–February 2, 2019
Influenza activity in the United States remained elevated through February 2, 2019, and is expected to continue for several more weeks. Influenza vaccination is the best way to reduce the risk of influenza and its potentially serious consequences, including hospitalizations in adults and deaths in children. Influenza antiviral medications are an important adjunct to vaccination in the treatment and prevention of influenza. Since December 2018, influenza activity increased overall and remained elevated through early February. Nationwide, influenza A(H1N1)pdm09 viruses have predominated, but in the southeastern United States influenza A(H3N2) viruses have predominated. As of February 2, 2019, this has been a low-severity influenza season, with a lower percentage of outpatient visits for influenza-like illness (ILI), lower rates of hospitalization, and fewer deaths attributed to pneumonia and influenza compared with recent seasons. Nevertheless, this season has resulted in many illnesses, hospitalizations and deaths, which are being reported in-season for the first time. The majority of the influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–19 Northern Hemisphere influenza vaccine viruses.

Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019
While flu vaccines vary in how well they work, vaccination can provide important protection against influenza. People age 6 months and older who have not yet been vaccinated this season should be vaccinated. People who are at high risk of serious flu complications and develop flu symptoms, and people who are very sick with flu should be treated early with antiviral medications. CDC recommends yearly influenza vaccination for children at least 6 months old and adults. Early estimates indicate that influenza vaccines have reduced the risk of medically attended influenza-related illness by almost half (47%) in vaccinated people so far this season. Vaccination reduced the rate of illness caused by the predominant influenza H1N1 virus by about 46 percent among patients of all ages, and by about 62 percent among children 6 months through 17 years of age. Vaccination provided similar protection to that seen in previous H1N1 seasons in children and in adults younger than age 50. For these estimates, 3,254 children and adults with acute respiratory illness were enrolled from November 23, 2018 to February 2, 2019 at five study sites with outpatient medical facilities in the United States.

Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness
The Advisory Committee on Immunization Practices now recommends routine hepatitis A (HepA) vaccination for all people ages 1 year and older who experience homelessness. In October 2018, the Advisory Committee on Immunization Practices (ACIP) unanimously approved updating the recommendations for HepA vaccine to include all people ages 1 year and older experiencing homelessness. The new recommendation is based on evidence showing the substantial public health and cost benefit of routine HepA vaccination for people who are homeless. Additionally, recent outbreaks of hepatitis A virus transmission have demonstrated the vulnerability of this population to this infection. Between 2016 and 2018, more than 7,000 cases of hepatitis A infection were reported in 12 states. The majority of these infections were among people reporting homelessness and/or injection or non-injection drug use. HepA vaccination for people who are homeless will protect these vulnerable individuals and reduce the risk of person-to-person outbreaks among this population.

Africa CDC   [to 16 Feb 2019]

https://au.int/en/africacdc

No new digest content identified.

China CDC 

http://www.chinacdc.cn/en/

New website launched…no “news” or “announcements” page identified. Link to National Health Commission of the People’s Republic of China not responding at inquiry [16 Feb 2019]

Announcements
 
 
Paul G. Allen Frontiers Group    [to 16 Feb 2019]
https://www.alleninstitute.org/news-press/
No new digest content identified.
 
 
BMGF – Gates Foundation  [to 16 Feb 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 16 Feb 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 16 Feb 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 16 Feb 2019]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 16 Feb 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center    [to 16 Feb 2019]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 16 Feb 2019]
http://www.ema.europa.eu/ema/
News and press releases
Role of big data for evaluation and supervision of medicines in the EU
15/02/2019
Recommendations for a path towards understanding the acceptability of evidence derived from ‘Big data’ in support of the evaluation and supervision of medicines by regulators were published today as part of a summary report of the Heads of Medicines Agencies (HMA) – EMA Joint Big Data task force . The recommendations and associated actions set out what needs to be addressed, but the mechanisms by which this may be achieved requires further focused work over the coming year. Stakeholders are invited to submit feedback and observations on the recommendations to inform the upcoming work of the group.

Massive amounts of data are generated on a daily basis through wearable devices, electronic health records, social media, clinical trials or spontaneous adverse reaction reports. There is no doubt that insights derived from this data will increasingly be used by regulators to assess the benefit-risk of medicines across their whole lifecycle. However, in order to benefit from and make prudent use of the data collected, regulators need a deeper understanding of the data landscape.

The HMA – EMA Joint Big Data task force is composed of experienced medicines regulators from 14 national competent authorities and EMA. In preparing the report, it assessed the generation of ‘big data’, their relevant sources and main formats, the methods for processing and analysing big data and the current state of expertise across the European medicines regulatory network.

A crucial step was defining ‘big data’ itself, a widely-used term that is lacking a commonly-accepted definition. The definition adopted by the task force reads as follows: “extremely large datasets which may be complex, multi-dimensional, unstructured and heterogeneous, which are accumulating rapidly and which may be analysed computationally to reveal patterns, trends and associations. In general, big data sets require advanced or specialised methods to provide an answer within reliable constraints.”

Six subgroups of data sources relevant to regulatory decision-making were considered by the taskforce: genomics, bioanalytical ‘omics (proteomics, etc.), clinical trials, observational data, spontaneous adverse drug reactions data and social media and mobile health data.

Stakeholders and members of the public are invited to submit their comments on the core recommendations in the summary report (not to exceed 1,000 words) to bigdatasec@dkma.dk

until 15 April 2019. In particular, views on prioritisation of future actions would be welcomed.

The feedback received will be taken into account in the next phase of the work of the task force. A newly-refined mandate for the group is in place for the next year to define next steps and prioritisation of actions.
 
 
European Vaccine Initiative  [to 16 Feb 2019]
http://www.euvaccine.eu/news-events
Latest news
No new digest content identified.
 
 
FDA [to 16 Feb 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.
 
 
Fondation Merieux  [to 16 Feb 2019]
http://www.fondation-merieux.org/
No new digest content identified.
 
 
Gavi [to 16 Feb 2019]
https://www.gavi.org/
13 February 2019
UK to host Gavi replenishment in 2020
Geneva, 13 February 2019 – The UK government today announced that it will host Gavi’s replenishment pledging conference in mid-2020.
The event will follow the successful Gavi pledging conference in Berlin in January 2015, which raised US $7.5 billion for the 2016-2020 period. Next year’s event will raise funds to support Gavi’s programmes from 2021-2025, and will aim to bring together contributions from donors.    These resources will be complemented by developing countries co-financing and the vaccine industry’s contributions. The investment case, which will set out the amount required, will be published later this year…

12 February 2019
Ethiopia introduces measles vaccine second dose with support from Gavi
Addis Ababa, 12 February 2019 – Ethiopia has introduced measles vaccine second dose (MCV2) vaccination into the routine immunization programme, with technical and financial support from Gavi, the Vaccine Alliance and the World Health Organisation. Around 3.3 million children throughout the country will receive measles vaccine second dose annually…
 
 
GHIT Fund   [to 16 Feb 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 16 Feb 2019]
https://www.theglobalfund.org/en/news/
News
No new digest content identified.
 
 
Hilleman Laboratories   [to 16 Feb 2019]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 16 Feb 2019]
http://www.humanvaccinesproject.org/media/press-releases/
February 13, 2019
Decoding the Human Immune System
For the first time ever, researchers are comprehensively sequencing the human immune system, which is billions of times larger than the human genome. In a new study published in Nature from the Human Vaccines Project, scientists have sequenced a key part of this vast and mysterious system — the genes encoding the circulating B cell receptor repertoire.
Sequencing these receptors in both adults and infants, the scientists found surprising overlaps that could provide potential new antibody targets for vaccines and therapeutics that work across populations. As part of a large multi-year initiative, this work seeks to define the genetic underpinnings of people’s ability to respond and adapt to an immense range of disease.
Led by scientists at Vanderbilt University Medical Center and the San Diego Supercomputer Center, this advancement is possible due to the merging of biological research with high-powered frontier supercomputing. While the Human Genome Project sequenced the human genome and led to the development of novel genomics tools, it did not tackle the size and complexity of the human immune system…
 
 
IAVI  [to 16 Feb 2019]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 16 Feb 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.
 
 
IVI   [to 16 Feb 2019]
http://www.ivi.int/
IVI News & Announcements
IVI and Yonsei University College of Medicine’s IIID to collaborate in vaccine R&D
On February 12 IVI exchanged a memorandum of understanding with the Institute of Immunology and Immunological Diseases (IIID), part of Yonsei University’s College of Medicine [Korea]. With this agreement, the two organizations are establishing a collaborative relationship in research and development of vaccines in order to help achieve the common goal of accelerating safe, effective, and affordable vaccines for people in developing countries and global health….
 
 
JEE Alliance  [to 16 Feb 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 16 Feb 2019]
http://www.msf.org/
Selected News; Project Updates, Reports [as presented on website]
Cameroon
Nothing to drink and nowhere to sleep for thousands who’ve fl…
Press Release 14 Feb 2019

Democratic Republic of Congo
Even during a widespread measles epidemic, we can sa…
Interview 14 Feb 2019

Yemen
MSF opens new emergency room in Ad Dahi hospital
Project Update 14 Feb 2019

DRC 2018 Ebola outbreaks
Potential new Ebola drugs being trialled in MSF treatment centres
Statement 12 Feb 2019
[See Emergencies above for detail]

El Salvador
Breaking the invisible barriers that divide neighbourhoods con…
Project Update 11 Feb 2019

Colombia
Buenaventura: “MSF fills a huge vacuum in helping victims of vio…
Interview 11 Feb 2019
 
 
NIH  [to 16 Feb 2019]
http://www.nih.gov/news-events/news-releases
February 14, 2019
NIH names Dr. Noni H. Byrnes director of the Center for Scientific Review
— National Institutes of Health Director Francis S. Collins M.D., Ph.D., announced today the selection of Noni H. Byrnes, Ph.D., as director of the NIH Center for Scientific Review (CSR), effective Feb. 17, 2019.
 
Patients to share personal journeys at NIH Rare Disease Day events
February 11, 2019 — Connect with patients about navigating life with a rare disease.
 
 
PATH  [to 16 Feb 2019]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 16 Feb 2019]
http://www.sabin.org/updates/pressreleases
Monday, February 11, 2019
The Bill & Melinda Gates Foundation and the Sabin Vaccine Institute Partner to Improve Vaccine Access by Strengthening Immunization Programs

WASHINGTON, DC – With the mutual goal of improving access to life-saving vaccines, the Bill & Melinda Gates Foundation recommitted its support to the Sabin Vaccine Institute (Sabin) to relaunch a global network for immunization managers. The success of immunization programs to reach populations with vaccines depends on excellent program management. Sabin will use the three-year, U.S. $3.5 million grant to provide national and sub-national immunization managers with training, education and networking opportunities, with an emphasis on strengthening management and leadership skills.

This initiative builds on the IAIM Network (International Association of Immunization Managers), established five years ago with support from the Bill & Melinda Gates Foundation to help immunization managers connect, share best practices and learn from trusted peers. The IAIM Network has become the world’s largest network for immunization managers, with more than 400 managers from over 120 countries engaging in virtual or in-person activities.

“We know that improving management capabilities and skills has a direct effect on program performance,” said Dr. Bruce Gellin, president of Global Immunization at Sabin. “This network will empower immunization managers to get answers, grow in their role and raise their collective voice.”…
 
 
UNAIDS [to 16 Feb 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
15 February 2019
Healthy populations for healthy economies in Africa

15 February 2019
Ethiopia demonstrates that communities deliver

14 February 2019
OAFLA to broaden its scope of work

14 February 2019
Taking action against HIV medicine stock-outs in the Bolivarian Republic of Venezuela

12 February 2019
AIDS care in the Californian desert

12 February 2019
UNAIDS is awarded the Science and Medicine Award at the 25th Annual Steve Chase Awards
 
 
UNICEF  [to 16 Feb 2019]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Press release
Thousands of children vaccinated in remote Rukban settlement amid severe lack of access to medical care
UNICEF, UN and Syrian Arab Red Crescent reach more than 40,000 people with life-saving supplies in largest-ever humanitarian convoy since the start of the Syria crisis
15/02/2019

Press release
UNHCR and UNICEF urge action in Europe to end childhood statelessness
14/02/2019

Press release
More than 3,000 children released from armed groups in South Sudan since conflict began, but thousands more continue to be used
12/02/2019

News note
Fast Facts: 10 facts illustrating why we must #EndChildMarriage
11/02/2019

Press release
Dubai Cares and UNICEF announce the Dubai Declaration on Early Childhood Development at the World Government Summit
Declaration is a follow-up to the official MENA launch of the Lancet Series Advancing Early Childhood Development
10/02/2019

Press release
13.5 million children now uprooted in Africa – including those displaced by conflict, poverty and climate change
On eve of African Union Summit, UNICEF urges African States to lead in the protection and empowerment of uprooted children
 
 
Vaccine Confidence Project  [to 16 Feb 2019]
http://www.vaccineconfidence.org/
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 16 Feb 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 16 Feb 2019]
https://wellcome.ac.uk/news
Opinion | 15 February 2019
This is a pivotal moment for clinical trial regulations
by Beth Thompson
Globally, clinical research is governed by guidelines established almost three decades ago. And Brexit is a looming issue for trials that take place in the UK. Wellcome’s Policy team is working to address both problems.
 
 
The Wistar Institute   [to 16 Feb 2019]
https://www.wistar.org/news/press-releases
Press Release    Feb. 15, 2019
Wistar’s David B. Weiner, Ph.D., Awarded Prestigious Scientific Achievement Award from Life Sciences Pennsylvania
PHILADELPHIA — (Feb. 15, 2019) — David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Research at The Wistar Institute, has been named the recipient of this year’s Scientific Achievement Award from Life Sciences Pennsylvania. The organization, with its more than 800-member companies, has a single mission to make Pennsylvania a hub of innovation by creating a business and public policy environment that fosters life sciences growth and success.

“Our Scientific Achievement Award recognizes a scientist in the Pennsylvania life sciences community who has demonstrated outstanding achievement by advancing scientific knowledge, innovation, and/or patient care,” said Christopher P. Molineaux, president & CEO of Life Sciences PA. “We can’t think of a better honoree this year than David – considered a founder of the field of synthetic DNA vaccines with more than 30 years of research contributions and scientific influence.”…
 
 
World Organisation for Animal Health (OIE)   [to 16 Feb 2019]
http://www.oie.int/en/for-the-media/press-releases/2018/
14/02/19
New report shows global shift in use of antibiotics in animals
[See Milestones above for detail]
 
::::::
 
BIO    [to 16 Feb 2019]
https://www.bio.org/insights/press-release
Feb 15 2019
BIO Statement on CMS Proposed Decision Memo for the CAR-T National Coverage Determination
Washington, DC (February 15, 2019) – Today, Biotechnology Innovation Organization (BIO) Executive Vice President for Health Policy, Dan Durham, issued the following statement r  regarding the CMS proposed decision memo for the CAR-T National Coverage Determination:
“We are further analyzing CMS’ released proposed decision memo for the National Coverage Determination for CAR T-cell therapy and look forward to providing the Agency with detailed comments in the coming weeks. It is critical that CMS coverage policies balance timely access to FDA-approved therapies across all potential appropriate settings of care, particularly when making determinations around innovations that represent significant advances in the delivery of treatment, such as CAR T. Further, such policy requirements should not be overly burdensome for providers, should be well aligned with FDA REMS requirements, and should provide enough flexibility as the class of medicines evolves.”
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 16 Feb 2019]
http://www.dcvmn.org/
No new digest content identified.
 
 
IFPMA   [to 16 Feb 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.
 
 
PhRMA    [to 16 Feb 2019]
http://www.phrma.org/press-room
No new digest content identified.
 
 
Industry Watch  [to 16 Feb 2019]
:: Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 February 12, 2019
   Interim data show vaccination with mRNA-1653 boosted serum neutralization titers against hMPV and PIV3 at all dose levels tested and was generally well tolerated
   Company plans to advance mRNA-1653 into a Phase 1b study in seropositive pediatric subjects

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 16 Feb 2019)

Research article
Comparison of influenza disease burden in older populations of Hong Kong and Brisbane: the impact of influenza and pneumococcal vaccination
Influenza and pneumococcal vaccine uptake in the older population aged 65 years or over of Hong Kong dramatically increased since the 2003 SARS outbreak. This study is aimed to evaluate the impact of increased…
Authors: Lin Yang, King Pan Chan, Chit Ming Wong, Susan Shui Seng Chiu, Ricardo J. Soares Magalhaes, Thuan Quoc Thach, Joseph Syrial Malik Peiris, Archie C. A. Clements and Wenbiao Hu
Citation: BMC Infectious Diseases 2019 19:162
Published on: 14 February 2019

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Feb 2019)

Research article
Epidemiological characteristics and trends of a Nationwide measles outbreak in Mongolia, 2015–2016
Mongolia was one of the four countries that received a measles-elimination certificate from the World Health Organization Regional Office for the Western Pacific in 2014. Following the outbreaks in many countr…
Authors: Oyunchimeg Orsoo, Yu Mon Saw, Enkhbold Sereenen, Buyanjargal Yadamsuren, Ariunsanaa Byambaa, Tetsuyoshi Kariya, Eiko Yamamoto and Nobuyuki Hamajima
Citation: BMC Public Health 2019 19:201
Published on: 15 February 2019

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Feb 2019)

Research article
Pertussis vaccination status and vaccine acceptance among medical students: multicenter study in Germany and Hungary
Medical students are at risk of contracting and transmitting infectious diseases such as pertussis. Complete vaccination status is important to protect own, patient and public health. Knowing own vaccination s…
Authors: Mandy Böhme, Karen Voigt, Erika Balogh, Antje Bergmann, Ferenc Horváth, Joachim Kugler, Jörg Schelling, Jeannine Schübel and Henna Riemenschneider
Citation: BMC Public Health 2019 19:182
Published on: 12 February 2019

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 16 Feb 2019)

Research note
Immunization coverage and factors associated with incomplete vaccination in children aged 12 to 59 months in health structures in Lomé
To estimate the immunization coverage among children admitted for consultation or hospitalization in health structures of Lomé.
Authors: Wendpouiré I. C. Zida-Compaore, Didier K. Ekouevi, Fifonsi A. Gbeasor-Komlanvi, Essèboè K. Sewu, Tetouyaba Blatome, Adama D. Gbadoe, Diparidè A. Agbèrè and Yawo Atakouma
Citation: BMC Research Notes 2019 12:84
Published on: 14 February 2019

Ethics & Human Research
Volume 41, Issue 1  January-February 2019
https://onlinelibrary.wiley.com/journal/25782363

New Challenges and Unresolved Issues
The inaugural issue of Ethics & Human Research (E&HR) marks an exciting milestone in The Hastings Centers’ 40‐year history of publishing a journal that focuses on the ethical, regulatory, and policy issues related to research with humans. Like its predecessor, IRB: Ethics & Human Research, E&HR will publish conceptual and empirical analyses on a wide range of topics related to the human research enterprise.

The journal’s name change conveys to the global community of authors and readers that E&HR is not solely about issues related to institutional review boards (IRBs) in the United States. The title shift provides an opportunity to identify new ethical, policy, and regulatory challenges that rapid developments in science, medicine, and regulatory frameworks bring to the conduct and oversight of human subjects research in the United States and elsewhere. Along with publishing work that investigates new challenges, E&HR aims not only to draw attention to unresolved issues but also to broaden the scope of issues for investigation and analysis in the field of human research ethics. The pieces in this inaugural issue identify several new challenges and hint at some of the unresolved issues and broader topics that merit further attention.

Global Public Health
Volume 14, 2019   Issue 4
http://www.tandfonline.com/toc/rgph20/current

Special Issue: Analysing power and politics in health policies and systems;
Guest Editors: Radhika Gore and Richard Parker 
introduction
Analysing power and politics in health policies and systems
Radhika Gore & Richard Parker
Pages: 481-488
Published online: 16 Feb 2019
ABSTRACT
This special issue of Global Public Health presents a collection of articles that analyse power and its mechanisms in health systems and health policy processes. Researchers have long noted that the influence of power is implicated throughout the global health field, yet theories and methods for examining power—its sources, workings, and effects—are rarely applied in health policy and systems research. By engaging with the social sciences and humanities, contributors to this collection aim to analytically sharpen and thematically broaden the study of power and politics in global health. Contributors analyse the exercise of power by actors typically considered powerful on the global stage as well as actors across the health system who may be powerful in national or local contexts. Additionally, the papers draw attention to actors, interest groups, and practices not usually viewed as politically salient in health policy and systems research in low- and middle-income countries. The papers not only analyse power but also identify ways to counteract it, such as by using human rights-based frameworks to investigate and challenge power asymmetries. Collectively, they show how researchers working on global health issues can theorise power and deepen political analysis of health policy and systems.

Humanitarian Exchange Magazine
Number 74,  February 2019
https://odihpn.org/magazine/communication-community-engagement-humanitarian-response/

Communication and community engagement in humanitarian response
This edition of Humanitarian Exchange, co-edited with Charles-Antoine Hofmann from the UN Children’s Fund (UNICEF), focuses on communication and community engagement. Despite promising progress, coherent and coordinated information is still not provided systematically to affected communities, and humanitarian responses take insufficient account of the views and feedback of affected people. In 2017, UNICEF, the International Federation of Red Cross and Red Crescent Societies (IFRC), the UN Office for the Coordination of Humanitarian Affairs (OCHA) and other partners came together under the auspices of the Communicating with Disaster Affected Communities (CDAC) Network to establish the Communication and Community Engagement (CCE) initiative, which aims to organise a collective service for communications and community engagement. The articles in this edition take stock of efforts to implement this initiative.

Drawing on lessons from 23 Peer 2 Peer Support missions, Alice Chatelet and Meg Sattler look at what’s needed to integrate CCE into the humanitarian architecture. Viviane Lucia Fluck and Dustin Barter discuss the institutional and practical barriers to implementing community feedback mechanisms. Bronwyn Russel analyses the performance of the Nepal inter-agency common feedback project; Justus Olielo and Charles-Antoine Hofmann outline the challenges of establishing common services in Yemen; and Gil Francis Arevalo reports on community engagement in preparedness and response in the Philippines. Ian McClelland and Frances Hill discuss emerging findings from a strategic partnership in the Philippines between the Humanitarian Innovation Fund and the Asian Disaster Reduction and Response Network.

Charlotte Lancaster describes how call centres in Afghanistan and Iraq are enhancing two-way communication with crisis-affected people. Mia Marzotto from Translators without Borders reflects on the importance of language and translation in communication and community engagement, and Ombretta Baggio and colleagues report on efforts to bring community perspectives into decision-making during an Ebola outbreak in the Democratic Republic of Congo. Ayo Degett highlights emerging findings from a Danish Refugee Council project on participation in humanitarian settings, and Jeff Carmel and Nick van Praag report on the Listen Learn Act (LLA) project. Geneviève Cyvoct and Alexandra T. Warner write on an innovative common platform to track the views of affected people in Chad. The edition ends with an article by Stewart Davies on collective accountability in the response to the Central Sulawesi earthquake.

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 16 Feb 2019]

Scoping Review
|   13 February 2019
Are malaria elimination efforts on right track? An analysis of gains achieved and challenges ahead
Authors: Sunil Dhiman

JAMA
February 12, 2019, Vol 321, No. 6, Pages 523-620
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Trust in Health Care
A Framework for Increasing Trust Between Patients and the Organizations That Care for Them
Thomas H. Lee, MD, MSc; Elizabeth A. McGlynn, PhD; Dana Gelb Safran, ScD
free access
JAMA. 2019;321(6):539-540. doi:10.1001/jama.2018.19186
This Viewpoint summarizes key findings and conclusions of a working group of health care leaders and patient advocates who participated in a 2018 American Board of Internal Medicine (ABIM) Foundation Forum on [Re]Building Trust, convened to identify and prioritize interventions to restore trust in health care teams, standards, measures, and systems.

JAMA
February 12, 2019, Vol 321, No. 6, Pages 523-620
http://jama.jamanetwork.com/issue.aspx

Editorial
Trust in Health Care
Howard Bauchner, MD

Journal of Evidence-Based Medicine
Volume 12, Issue S1  Pages: 1-34  January 2019
https://onlinelibrary.wiley.com/toc/17565391/current

7th Meeting of the COMET Initiative (VII), Thursday 15th and Friday 16th November 2018, De Rode Hoed, Amsterdam
On the 15^th and 16^th November 2018, the Core Outcome Measures in Effectiveness Trials (COMET) Initiative held its seventh international meeting. After success at COMET VI, the COMET meeting returned to De Rode Hoed (The Red Hat) in Amsterdam for their second consecutive meeting. One‐hundred and fifteen participants gathered from around the world, coming from five continents and 18 countries.

Journal of Public Health Policy
Volume 40, Issue 1, March 2019
https://link.springer.com/journal/41271/40/1

Original Article
The World Breastfeeding Trends Initiative: Implementation of the Global Strategy for Infant and Young Child Feeding in 84 countries
Arun Gupta, Shoba Suri, J. P. Dadhich, Marta Trejos… Pages 35-65

Journal of Public Health Policy
Volume 40, Issue 1, March 2019
https://link.springer.com/journal/41271/40/1

Viewpoint
A public health framework for the regulation of marketing
Anthony Biglan, Mark Van Ryzin, Erika Westling Pages 66-75

Journal of Public Health Policy
Volume 40, Issue 1, March 2019
https://link.springer.com/journal/41271/40/1

Viewpoint
Barriers to the evaluation of evidence-based public health policy
Megan Freund, Alison Zucca, Robert Sanson-Fisher… Pages 114-125

The Lancet
Feb 16, 2019  Volume 393  Number 10172p611-716, e29
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Russia’s burgeoning HIV epidemic
The Lancet
While some countries in western Europe celebrate relative successes in the treatment and control of HIV, a burgeoning epidemic in the eastern part of the region poses a continued threat to progress.

A report, published Feb 4, from the European Centre for Disease Prevention and Control underlines the inequality of treatment and care for people living with HIV in Europe and central Asia. The report states that in these regions overall, one of five people living with HIV (PLHIV) is unaware of their status and only 43% of PLHIV have viral loads low enough to prevent transmission—substantially than the UNAIDS goal of 73%. The failure to reach the target is largely due to low rates of viral suppression reported from countries in the central and eastern subregions of the WHO European Region. Specifically, in Russia, the number of PLHIV is reported as 998 525, with only 26% achieving viral suppression and in Ukraine, the number is 244 000, with 23% achieving viral suppression. However, the situation in Russia is worthy of closer examination because the findings in the report are based on estimates from data provided for the first time by the country’s Ministry of Health to UNAIDS, in 2017, and covering the year ending 2016.

The latest information, obtained directly by us from the Ministry, covers the year ending 2017, and reports the number of newly registered PLHIV has increased by 105 844. Clearly, this is not an exact measure of incidence, but it gives an indication that numbers continue to rise unabated. Reasons for the absence of progress in Russia are numerous and include insufficient access to sterile injecting equipment, unavailability of opioid substitution therapy, and a shortage of treatment in populations where it is most needed, namely people who inject drugs and their partners, sex workers, and men who have sex with men.

The release of HIV data by Russia is to be applauded. But if serious inroads are to be made into the epidemic, then attention must now turn to treatment of key, marginalised populations of PLHIV.

The Lancet
Feb 16, 2019  Volume 393  Number 10172p611-716, e29
https://www.thelancet.com/journals/lancet/issue/current

Comment
Ebola in the Democratic Republic of the Congo: time to sound a global alert?

Lawrence Gostin, Alexandra Phelan, Alex Godwin Coutinho, Mark Eccleston-Turner, Ngozi Erondu, Oyebanji Filani, Tom Inglesby, Rebecca Katz, Allan Maleche, Jennifer B Nuzzo, Oyewale Tomori, Matthew Kavanagh

[See Milestones above for full text]

We call upon the WHO Director-General to reconvene the EC to review the grounds for a PHEIC declaration. He should invite states, the UN, and NGOs to attend and submit evidence. 10  The United Nations Organization Stabilization Mission in the Democratic Republic of the Congo (MONUSCO), UNHCR, the UN Refugee Agency, and civil society could provide critical information. The EC should recommend proactive measures on health, diplomacy, security, and community engagement. Concrete recommendations could specify the level and kind of resources needed and composition of security and diplomatic assets.

A PHEIC is a clarion call to galvanise high-level political, financial, and technical support. A PHEIC would provide a clear signal from the world’s global health body that UN leadership is urgent. A PHEIC also empowers the WHO Director-General to make temporary, non-binding recommendations that have normative force.10

The IHR do not specify any surge in authority or financing when declaring a PHEIC. In the past, states did not heed WHO warnings that travel and trade restrictions are harmful. During the west African Ebola epidemic, 58 states restricted travel from affected areas, and during the 2009 influenza A H1N1 pandemic, states imposed trade and travel restrictions.12,13,14]

Trade or travel barriers in the DRC would have devastating impacts. WHO, with UN support, should take active steps to prevent unlawful and harmful restrictions. In 2009, WHO and the World Trade Organization (WTO) criticised governments that took non-evidence-based actions; going forward, WHO and WTO could publicly name non-compliant countries. Governments should also agree to dispute resolution, including binding IHR arbitration.10

If a PHEIC escalated conflict by raising the profile of the international response, it would be deeply concerning. Recent elections in DRC were clouded by concerns about vote-rigging, unsettling lines of power and legitimacy. Armed groups have used violence to generate chaos. A PHEIC could increase incentives to target Ebola responders to gain leverage. As in South Sudan, armed groups could manipulate aid for non-humanitarian purposes.15 Like any complex multilateral negotiation, cultural competence and smart diplomacy are required. Outsiders are unlikely to be privy to all on-the-ground realities and risks.

The IHR were designed to respond to a health emergency like the DRC Ebola epidemic. We urge the WHO Director-General to reconvene the EC and re-assess the declaration of a PHEIC. The UN and governments should increase support for WHO and partners. If the IHR fails, or worse, increases political instability, it will require urgent reform.

State non-compliance should not obscure the value of the IHR in establishing norms of rapid identification, notification, and response. The IHR require states to develop health-system capacities, assessed by WHO’s Joint External Evaluation. IHR reform should focus on technical and financial assistance for national health capacities. A PHEIC should trigger surge capacity in relation to authority and finances, with effective mechanisms to gain state compliance.

WHO has shown leadership and operational endurance, working tirelessly to combat the DRC Ebola epidemic. But WHO and partners cannot succeed alone. We live at a political moment when international solutions to collective threats are increasingly hard to achieve. But WHO and the UN system will be called upon with ever-greater frequency in the future to manage complex humanitarian crises. We must plan for a future in which political violence and instability become the new abnormal.

[References at title link above]

Nature 
Volume 566 Issue 7743, 14 February 2019
http://www.nature.com/nature/current_issue.html

Editorial | 11 February 2019
Trump’s goal to eradicate the HIV epidemic in the United States is achievable — yet remote
The president’s pledge rings hollow without a major shift in policy and rhetoric.

Nature 
Volume 566 Issue 7743, 14 February 2019
http://www.nature.com/nature/current_issue.html

Editorial | 13 February 2019
Artificial intelligence alone won’t solve the complexity of Earth sciences
Studies of complex climate and ocean systems could gain from a hybrid between artificial intelligence and physical modelling.

Nature 
Volume 566 Issue 7743, 14 February 2019
http://www.nature.com/nature/current_issue.html

Comment | 11 February 2019
Overdue: a US advisory board for research integrity
Research needs an authoritative forum to hash out collective problems, argue C. K. Gunsalus, Marcia K. McNutt and colleagues.

1. K. Gunsalus, Marcia K. McNutt[…]& Robert M. Nerem

New England Journal of Medicine
February 14, 2019   Vol. 380 No. 7
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Brazil’s Fight against Hepatitis C — Universalism, Local Production, and Patents
Elize M. da Fonseca, Ph.D., Kenneth Shadlen, Ph.D., and Francisco I. Bastos, M.D., Ph.D.
Brazil’s strategy for addressing hepatitis C, which combines evidence-based treatment protocols and innovative initiatives for local production of generic direct-acting antiviral drugs, needs to be considered in light of ongoing conflicts over pharmaceutical patents.

PharmacoEconomics & Outcomes News
Volume 821, Issue 1, February 2019
https://link.springer.com/journal/40274/821/1

Clinical study
Global forecast on medicine use
IQVIA Institute. The Global Use of Medicine in 2019 and Outlook to 2023. Internet Document : 29 Jan 2019. Available from: URL: https://www.iqvia.com/institute/reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023

PLoS One
http://www.plosone.org/
[Accessed 16 Feb 2019]

Research Article
Barriers to effective uptake and provision of immunization in a rural district in Uganda
Oliver Ombeva Malande, Deogratias Munube, Rachel Nakatugga Afaayo, Kisakye Annet, Bongomin Bodo, Andrew Bakainaga, Elizabeth Ayebare, Sam Njunwamukama, Edison Arwanire Mworozi, Andrew Munyalo Musyoki
Research Article | published 14 Feb 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0212270

PLoS One
http://www.plosone.org/
[Accessed 16 Feb 2019]

The impact of supplementary immunization activities on routine vaccination coverage: An instrumental variable analysis in five low-income countries
Averi Chakrabarti, Karen A. Grépin, Stéphane Helleringer
Research Article | published 14 Feb 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0212049

Prehospital & Disaster Medicine
Volume 34 – Issue 1 – February 2019
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue

Guest Editorial
Character Disorders among Autocratic World Leaders and the Impact on Health Security, Human Rights, and Humanitarian Care
Frederick M. Burkle
https://doi.org/10.1017/S1049023X18001280
Published online: 15 January 2019, pp. 2-7
Abstract
The development of autocratic leaders in history reveals that many share severe character disorders that are consistently similar across borders and cultures. Diplomats and humanitarians negotiating for access to populations in-need and security of their programs, especially in health, must understand the limitations placed on the traditional negotiation process. These shared character traits stem from a cognitive and emotional developmental arrest in both childhood and adolescence resulting in fixed, life-long, concrete thinking patterns. They fail to attain the last stage of mental and emotional development, that of abstract thinking, which is necessary for critical reasoning that allows one to consider the broader significance of ideas and information rather than depend on concrete details and impulses alone. These autocratic leaders have limited capacity for empathy, love, guilt, or anxiety that become developmentally permanent and guide everyday decision making. Character or personality traits that perpetuate the lives of autocratic leaders are further distinguished by sociopathic and narcissistic behaviors that self-serve to cover their constant fear of insecurity and the insatiable need for power. Human rights, humanitarian care, and population-based health security are examples of what has consistently been sacrificed under autocratic rule. Today, with the worst global loss of democratic leadership ever seen since WWII, leaders with these character traits now rule in major countries of the world. While history teaches us of battles and conflicts that result from such flawed leadership, it lacks explanations of why autocratic behaviors consistently emerge and dominate many societies. Building multidisciplinary capacity and capability in societies among democracies to limit or cease such authoritarian dominance first begins with a developmental understanding of why autocrats exist and persist in externalizing their pathological behaviors on unsuspecting and vulnerable populations, and the limitations they place on negotiations.

Science         
15 February 2019  Vol 363, Issue 6428
http://www.sciencemag.org/current.dtl

In Depth 
DOE to limit foreign research collaborations
By Jeffrey Mervis
Science15 Feb 2019 : 675-676 Restricted Access
Recent memos describe crackdown on grantees and on lab scientists with foreign ties.

Science         
15 February 2019  Vol 363, Issue 6428
http://www.sciencemag.org/current.dtl

Controversial flu studies can resume, U.S. panel says
By Jocelyn Kaiser
Science15 Feb 2019 : 676-677 Restricted Access
Critics complain of lack of transparency in decision that allows efforts to create potentially risky virus strains.

Science         
15 February 2019  Vol 363, Issue 6428
http://www.sciencemag.org/current.dtl

Measles epidemic in Ukraine drove troubling European year
By Meredith Wadman
Science15 Feb 2019 : 677-678 Restricted Access
War and distrust of vaccines seeded ongoing outbreak

Science Translational Medicine
13 February 2019  Vol 11, Issue 479
http://stm.sciencemag.org/

Focus
Biology, biography, and the translational gap
By Pamela Summers-Trio, Allison Hayes-Conroy, Burton Singer, Ralph I. Horwitz
Science Translational Medicine13 Feb 2019 Full Access
Medicine-based evidence integrates biology and biography to help eliminate the translational gap between research and the clinic.

Social Science & Medicine
Volume 222  Pages 1-376 (February 2019)
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/221/suppl/C

Research article  Abstract only
Exploring the meaning of pro-vaccine activism across two countries
Samantha Vanderslott
Pages 59-66
Abstract
While vaccine-critical activism has been widely documented and discussed, comparatively little has been said about the concerted response of pro-vaccine activists defending the majority view. This paper explores two case studies of pro-vaccine activism in Australia and the United States (US). It shows how pro-vaccine views and behaviours can take varying forms due to different aims and methods of engagement – oppositional counteractivities in favour of vaccination in Australia, and issue-based advocacy as part of a political alliance in the US. The focus in Australia comes from a pro-science stance and includes ‘skeptics’ against pseudoscience directly opposing vaccine-critical groups. In the US, the focus takes the form of an issue-specific campaign that has arisen from existing pro-vaccine parent blogs and discussion groups pushing for policy change rather than public confrontation. These case studies exemplify how pro-vaccine activism can take varying forms of either reinforcing the mainstream view or countering digression from it. Drawing on qualitative research, this paper aims to examine the types of practices and strategies employed by activists to voice their support of vaccination, and discusses the means, messages, and motivations of pro-vaccine activism. It ends with an argument for why a study – of public support for in addition to studying public opposition to vaccination – can help to better understand vaccination views and behaviours. These findings have wider implications for the study of counter-activism and the polarisation of civil society groups.

Vaccine
Volume 37, Issue 10  Pages 1255-1376 (28 February 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/10

Research article  Abstract only
Effectiveness of an intervention campaign on influenza vaccination of professionals in nursing homes: A cluster-randomized controlled trial
France Borgey, Liliane Henry, Josiane Lebeltel, Pascale Lescure, … Pascal Thibon
Pages 1260-1265

Vaccine
Volume 37, Issue 10  Pages 1255-1376 (28 February 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/10
Research article  Abstract only

Research article  Abstract only
A pathway to developing and testing quality measures aimed at improving adult vaccination rates in the United States
Angela K. Shen, Amy V. Groom, Diane L. Leach, Carolyn B. Bridges, … Litjen Tan
Pages 1277-1283

Vaccine
Volume 37, Issue 10  Pages 1255-1376 (28 February 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/10

Research article  Abstract only
A population-based study of maternal and infant factors influencing influenza vaccination among young children born in Colorado from 2008 to 2016
Suchitra Rao, Musheng Alishahi, Lauren De Crescenzo, Amanda F. Dempsey
Pages 1293-1298

Vaccine
Volume 37, Issue 10  Pages 1255-1376 (28 February 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/10

Research article  Abstract only
Parent report of provider HPV vaccine communication strategies used during a randomized, controlled trial of a provider communication intervention
A.F. Dempsey, J. Pyrzanowski, E.J. Campagna, S. Lockhart, S.T. O’Leary
Pages 1307-1312

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

No new digest content identified.

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
BBC
http://www.bbc.co.uk/
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
CNN
https://www.cnn.com/
Accessed 16 Feb 2019
Amid measles outbreaks, Facebook considering how to reduce spread of anti-vaccine content
By Jacqueline Howard, CNN
Updated 2:28 PM ET, Fri February 15, 2019
(CNN)Facebook is looking into suppressing certain anti-vaccine messaging on its social platform, a move that raises questions about free speech and public health.
“We’ve taken steps to reduce the distribution of health-related misinformation on Facebook, but we know we have more to do. We’re currently working with outside experts on additional changes that we’ll be announcing soon,” a representative for the social media giant said Friday.
In recent years, anti-vaccination groups have been vocal on Facebook, frequently sharing and posting information against vaccines and their safety. At the same time, there has been a rise in cases of measles and other infectious diseases across the United States…
…Arthur Caplan, a professor and founding head of the Division of Medical Ethics at NYU Langone Health in New York, said that he is “very supportive” of Facebook’s new efforts to police anti-vaccine messaging.
“They don’t have to be a platform for lying, for fearmongering, for inaccuracy, especially when children are put at risk,” said Caplan, who has written about anti-vaccination groups’ social media presence in the journal Human Vaccines & Immunotherapeutics.
“I’m not trying to say that somebody can’t take positions against vaccines on Facebook,” he said. “I know people are going to say this is an intrusion into free speech — many anti-vaxxers will say that — but no one is saying you can’t be anti-vaccination. What we’re saying is, you can’t lie. You can’t fearmonger.”…
 
 
The Economist
http://www.economist.com/
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 16 Feb 2019
Is There Any Benefit Of “Natural Immunity” When It Comes To Infections Like Measles?
In the midst of one of the largest worldwide measles outbreaks since the initiation of the measles vaccine, those with large social media platforms are spreading inaccurate medical information regarding the safety and efficacy of immunization…
By  Nina Shapiro  Contributor
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 16 Feb 2019
Vaccines and immunisation
Measles: WHO says cases have jumped 50%
Falsehoods spread by ‘anti-vax’ movement in part to blame for backsliding in progress against potentially deadly illness, experts say
Rebecca Ratcliffe and agencies
Fri 15 Feb 2019
Anti-vaccine scepticism, conflict and poor access fuelled a 50% increase in measles cases last year, according to the World Health Organization.
The UN health agency said the resurgence was happening at a global level, including in wealthy nations where vaccination coverage has historically been high.
“Our data is showing that there is a substantial increase in measles cases. We’re seeing this in all regions,” said Katherine O’Brien, WHO’s director of immunisation and vaccines. “We’re having outbreaks that are protracted, that are sizeable and that are growing,. This is not an isolated problem.”
The figures are a worrying sign of the vast reach of vaccine-scepticism, said Heidi Larson, director of the Vaccine Confidence Project at the London School of Hygiene and Tropical Medicine. “It’s very serious. Historically measles outbreaks go up and down but this is a pretty dramatic increase.”…
 
 
New Yorker
http://www.newyorker.com/
Accessed 16 Feb 2019
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 16 Feb 2019
U.S.
Washington Lawmakers Advance Limits on Vaccine Exemptions
Washington state lawmakers advanced a measure Friday that would remove parents’ ability to claim a personal or philosophical exemption to vaccinating their school-age children for measles as the Pacific Northwest struggles with an outbreak of the contagious virus.
Feb. 15
 
 
Africa
Nearly 1,000 Madagascar Children Dead of Measles Since October: WHO
At least 922 children and young adults have died of measles in Madagascar since October, despite a huge emergency vaccination program, the World Health Organization (WHO) said on Thursday.
Feb. 15
 
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 16 Feb 2019
Review & Outlook
Didn’t We Already Beat Measles?
By The Editorial Board
Feb. 12, 2019 7:06 pm ET
Fifty-three cases are now confirmed, most in unvaccinated kids.
 
 
Washington Post
http://www.washingtonpost.com/
Accessed 16 Feb 2019
Anti-vaxxers are spreading conspiracy theories on Facebook, and the company is struggling to stop them
By Taylor Telford
February 13
As a disturbing number of measles outbreaks crop up across the United States, Facebook is facing challenges combating widespread misinformation about vaccinations on its platform, which has become a haven for the anti-vaccination movement

Think Tanks et al
 
Brookings
http://www.brookings.edu/
Accessed 16 Feb 2019
[No new relevant content]

Center for Global Development  
http://www.cgdev.org/page/press-center
February 7, 2019
Gavi Going Forward: Immunization for Every Child Everywhere?
In December 2018, the Gavi Alliance hosted a mid-term review to assess progress towards its core purpose: “reach every child everywhere with vaccines against preventable diseases.” The good news is that there’s been advances on new vaccine introductions, and an estimated 65 million children were immunized with Gavi-supported new and underutilized vaccines in 2017.     The bad news? There is still huge variability on the measure that counts most for building herd immunity and reducing vaccine-preventable disease: full vaccination for age among children under 2 years old.
Amanda Glassman and Liesl Schnabel

CSIS
https://www.csis.org/
Accessed 16 Feb 2019
Transcript
Saving Lives in a Time of Crisis: Why the Global Humanitarian System Matters
February 14, 2019

Council on Foreign Relations
http://www.cfr.org/
Accessed 16 Feb 2019
[No new relevant content]

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 16 Feb 2019
February 15, 2019 News Release
Analysis Finds that Medications for Hepatitis C and HIV/AIDS Are the Costliest Group of Outpatient Prescription Drugs for Medicaid, While Diabetes Drugs Have Posted the Sharpest Rise in Costs 
Antiviral medications, including those that treat hepatitis C and HIV/AIDS, cost the Medicaid program more money (before rebates) than any other group of outpatient prescription drugs for each year from 2014 to 2017, according to a new KFF analysis.

Milestones :: Perspectives

::::::
::::::

Measles in Europe: record number of both sick and immunized
7 February 2019 | WHO Europe News release
More children in the WHO European Region are being vaccinated against measles than ever before; but progress has been uneven between and within countries, leaving increasing clusters of susceptible individuals unprotected, and resulting in a record number of people affected by the virus in 2018. In light of measles data for the year 2018 released today, WHO urges European countries to target their interventions to those places and groups where immunization gaps persist.

Measles killed 72 children and adults in the European Region in 2018. According to monthly country reports for January to December 2018 (received as of 01 February 2019), 82 596 people in 47 of 53 countries contracted measles. In countries reporting hospitalization data, nearly 2/3 (61%) of measles cases were hospitalized. The total number of people infected with the virus in 2018 was the highest this decade: 3 times the total reported in 2017 and 15 times the record low number of people affected in 2016.

The surge in measles cases in 2018 followed a year in which the European Region achieved its highest ever estimated coverage for the second dose of measles vaccination (90% in 2017). More children in the Region received the full two-dose series on time, according to their countries’ immunization schedules, in 2017 than in any year since WHO started collecting data on the second dose in 2000. Coverage with the first dose of the vaccine also increased slightly to 95%, the highest level since 2013. However, progress in the Region, based on achievements at the national level, can mask gaps at subnational levels, which are often not recognized until outbreaks occur.

“The picture for 2018 makes it clear that the current pace of progress in raising immunization rates will be insufficient to stop measles circulation. While data indicate exceptionally high immunization coverage at regional level, they also reflect a record number affected and killed by the disease. This means that gaps at local level still offer an open door to the virus,” says Dr Zsuzsanna Jakab. “We cannot achieve healthier populations globally, as promised in WHO’s vision for the coming five years, if we do not work locally. We must do more and do it better to protect each and every person from diseases that can be easily avoided.”…

Featured Journal Content

Emerging Infectious Diseases
17 Apr 2019, 25(4)] Original Publication Date: 1/30/2019
Prespective

Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas
Alberto E. Paniz-Mondolfi , Adriana Tami, Maria E. Grillet, Marilianna Márquez, Juan Hernández-Villena, María A. Escalona-Rodríguez, Gabriela M. Blohm, Isis Mejías, Huníades Urbina-Medina, Alejandro Rísquez, Julio Castro, Ana Carvajal, Carlos Walter, María G. López, Philipp Schwabl, Luis Hernández-Castro, Michael A. Miles, Peter J. Hotez, John Lednicky, J. Glenn Morris, James Crainey, Sergio Luz, Juan D. Ramírez, Emilia Sordillo, Martin Llewellyn, Merari Canache, María Araque, and José Oletta
Abstract
Venezuela’s tumbling economy and authoritarian rule have precipitated an unprecedented humanitarian crisis. Hyperinflation rates now exceed 45,000%, and Venezuela’s health system is in free fall. The country is experiencing a massive exodus of biomedical scientists and qualified healthcare professionals. Reemergence of arthropod-borne and vaccine-preventable diseases has sparked serious epidemics that also affect neighboring countries. In this article, we discuss the ongoing epidemics of measles and diphtheria in Venezuela and their disproportionate impact on indigenous populations. We also discuss the potential for reemergence of poliomyelitis and conclude that action to halt the spread of vaccine-preventable diseases within Venezuela is a matter of urgency for the country and the region. We further provide specific recommendations for addressing this crisis.

[Excerpt]
Recommendations
According to the evaluation approach recommended by WHO, the risk level of the ongoing outbreaks in Venezuela is high. A correspondingly strong response is needed to curtail the expanse of these epidemics. We propose the following measures.
:: Global and hemispheric health authorities should urge the Venezuela government to allow the establishment of a humanitarian channel to provide immediate relief efforts addressing extreme food and medicine shortages.

:: Epidemiologic surveillance programs, early reporting, and rapid response systems should be restored immediately. Strengthening of infection control practices in healthcare facilities should be implemented with the aid of international agencies while ensuring public health neutrality.

:: Emergency relief operations should be put into effect across borders along with authorities in Colombia and Brazil to ameliorate the effects of massive migration by implementation of early nutritional and immunization interventions.

:: International agencies should support regional efforts in neighboring countries to promote simultaneous massive vaccination campaigns and vaccination of all refugees from Venezuela arriving in host community populations.

:: Adequate supplies for mass vaccination and routine immunization should be ensured, and additional adjunct supplies (e.g., diphtheria antitoxin) should be stockpiled to assist in the establishment of standard treatment protocols and epidemic rapid response measures. These methods are crucial for healthcare delivery and mass vaccination catch-up campaigns to head off the resurgence of vaccine-preventable diseases in Venezuela.

:: In areas with low vaccination coverage, improving surveillance for early case detection and increasing vaccination coverage in high-risk age groups should be mandatory. Furthermore, Venezuela is in urgent need to reconstruct its devastated healthcare system, secure sustainable food and medication access, and reinstall proper sanitation policies to reduce the burden of diseases.

On September 27, 2018, the United Nations Human Rights Council adopted a resolution on Venezuela signaling the gravity of the human rights situation and the growing concern by governments worldwide about the country’s humanitarian crisis, including aspects such as malnutrition and the upsurge of preventable diseases (50). PAHO–WHO faces an enormous challenge in attending, without interference, to the complex emergency that affects Venezuela. Emergency funds must be released to acquire medicines, vaccines, laboratory reagents, and other supplies for health programs. As Venezuela rapidly becomes a regional nidus for the emergence of vaccine-preventable diseases, it must take decisive action now alongside regional and national partners to target this emerging regional crisis.

::::::
::::::

Featured Journal Content

 
The role of National Immunisation Technical Advisory Groups in evidence-informed decision-making – Enablers, constraints and future support options
ODI  Research reports and studies | February 2019 :: 48 pages
Anne Buffardi and Susan Njambi-Szlapka
PDF: https://www.odi.org/sites/odi.org.uk/files/resource-documents/12599.pdf
 
Executive Summary [Excerpt]
National Immunisation Technical Advisory Groups (NITAGs) are multidisciplinary groups of national experts who provide independent advice to policy-makers on issues related to immunisation and vaccines, based on evidence and the national context. The Global Vaccine Action Plan (GVAP) 2011–2020 and 2017 World Health Assembly resolution call on governments to establish and strengthen these advisory bodies, acknowledging their pivotal role in decision-making and in achieving national health goals. Although the number of NITAGs doubled between 2010 and 2016, accelerated progress is needed in order to meet the goal of a functional NITAG in all countries by 2020.
 
This report presents the findings of a scoping exercise initiated by the Wellcome Trust and the World Health Organization to determine how different types of NITAGs could be supported in the coming years. It is written for organisations who are familiar with and considering supporting the next phase of NITAGs’ development, NITAG members, and national and global stakeholders with whom NITAGs engage…
 
…Donors, the WHO and the Global NITAG Network (GNN) will continue to play important roles in supporting core NITAG functions and the expansion and embedding of NITAGs’ role in evidence-informed decision-making processes. To jointly move this work forward, three interdependent actions are most pressing:
:: Donors need to define their roles and more actively coordinate among themselves.
:: Donors also need to be more explicit in communicating what they can fund and how NITAGs can access these resources.
:: The WHO and the GNN need to clarify the ‘ask’ to donors and develop an investment case with defined national, regional and global support activities.

Emergencies 

POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 6 February 2019
:: The 144th Session of the Executive Board concluded on 1 February with a renewed support from the public health leadership for a final push to end polio. Read more about polio eradication efforts and the report by the EB on polio eradication here.
:: The Global Surveillance Action Plan 2018-2020 is now online. The GPSAP aims to support endemic, outbreak, and high-risk countries in evaluating and increasing the sensitivity of their surveillance systems. 

Summary of new viruses this week:
:: Afghanistan – Afghanistan- one case of wild poliovirus type 1 (WPV1);
:: Pakistan – one case of WPV1 and six WPV1-positive environmental samples;
:: Niger – one case of circulating vaccine derived poliovirus (VDPV2). five WPV1 positive environmental samples.

::::::
::::::

 
Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies  [to 9 Feb 2019]
Democratic Republic of the Congo
:: Ebola virus disease – Democratic Republic of the Congo   7 February 2019
…During the last 21 days (16 January – 5 February 2019), 119 new cases have been reported from 13 health zones (Figure 2), including: Katwa (75), Butembo (9), Beni (8), Kyondo (5), Kayna (5), Oicha (4), Manguredjipa (4), Biena (2), Kalunguta (2), Mabalako (2), Masereka (1), Mutwanga (1), and Vuhovi (1)². Current epidemiological analyses points to nosocomial transmission due to poor infection prevention and control (IPC) practices, persistent delays in detection and isolation of new cases, frequent community deaths (and subsequent contact with deceased), and transmission within family and community networks, as the main drivers of ongoing disease transmission. Insecurity and pockets of community resistance have continuously stifled efforts to combat these risks; nevertheless, response teams remain committed to actively strengthening community trust and participation in all affected areas, and are beginning to observe tangible improvements in Katwa and elsewhere….

:: 27: Situation report on the Ebola outbreak in North Kivu  5 February 2019

…Case management
On 24 November 2018, the MoH announced the launch of a randomized control trial for Ebola therapeutics. This is ongoing, with all confirmed cases in ETCs receiving therapy under the compassionate use protocol, together with supportive care.
As of 3 February 2018, 194 patients were admitted to Ebola transit and treatment centres. Among nine treatment ETCs and transit centres (TC), two have bed occupancy of more than 100% (Katwa ETC and Beni TC).
Patient sorting in Beni hospital and Beni ETC is being supervised; community re-integration of two cured cases is ongoing in Kirumba and Kanyabayonga.
…Implementation of ring vaccination protocol
As of 3 February 2019, a cumulative total of 73,309 people have been vaccinated since the start of the outbreak.
The Immunization Commission is being supported in their efforts to persuade contacts to be vaccinated in Kivika, Kambuli and Mukuna in Katwa health zone.

Bangladesh – Rohingya crisis – No new digest announcements identified  
Myanmar – No new digest announcements identified  
Nigeria – No new digest announcements identified
Somalia – No new digest announcements identified
South Sudan – No new digest announcements identified  
Syrian Arab Republic – No new digest announcements identified  
Yemen – No new digest announcements identified

 
::::::
 
WHO Grade 2 Emergencies  [to 9 Feb 2019]
Brazil (in Portugese)
:: Sarampo na Europa: número recorde de pessoas doentes e imunizadas  7 de fevereiro de 2019

Libya
:: WHO warns of increasing attacks on health facilities in Libya
5 February 2019 – The World Health Organization (WHO) warns of increasing attacks on health facilities and workers in both frequency and scale. WHO has documented more than 41 attacks targeting health workers and facilities throughout 2018–2019 across the country. These attacks resulted in 6 health workers and patients killed and 25 health workers injured. An additional seven health workers were also assaulted during this period…

Cameroon  – No new digest announcements identified
Central African Republic  – No new digest announcements identified
Ethiopia – No new digest announcements identified
Hurricane Irma and Maria in the Caribbean – No new digest announcements identified
Iraq – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Niger – No new digest announcements identified
occupied Palestinian territory  – No new digest announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new digest announcements identified
Sudan – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified

::::::
 
WHO Grade 1 Emergencies  [to 9 Feb 2019]
Afghanistan
Chad
Indonesia – Sulawesi earthquake 2018
Kenya
Lao People’s Democratic Republic
Mali
Namibia – viral hepatitis
Peru
Philippines – Tyhpoon Mangkhut
Tanzania
 
::::::
 
WHO AFRO Outbreaks – Week 05: 26 January – 01 February 2019
The WHO Health Emergencies Programme is currently monitoring 60 events in the region. This week’s edition covers key new and ongoing events, including:
:: Ebola virus disease in the Democratic Republic of the Congo
:: Lassa fever in Nigeria
:: Cholera in Burundi
:: Humanitarian crisis in Democratic Republic of the Congo
:: Humanitarian crisis in Ethiopia.

::::::
:::::: 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Yemen
:: Yemen: Hajjah Governorate – Flash Update 2 | 28 January-3 Feb …
Syrian Arab Republic   – No new digest announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia 
:: Ethiopia Humanitarian Bulletin Issue #2 | 21 January-03 Febr …

Somalia 
:: Humanitarian Bulletin Somalia, 1 January – 5 February 2019 …
 
::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.
 
 
EBOLA/EVD  [to 9 Feb 2019]
http://www.who.int/ebola/en/
:: 27: Situation report on the Ebola outbreak in North Kivu  5 February 2019
:: Ebola virus disease – Democratic Republic of the Congo   7 February 2019
 
 
MERS-CoV [to 9 Feb 2019]
http://who.int/emergencies/mers-cov/en/
– No new digest announcements identified.
 
 
Yellow Fever  [to 9 Feb 2019]
http://www.who.int/csr/disease/yellowfev/en/
– No new digest announcements identified.
 
 
Zika virus  [to 9 Feb 2019]
http://www.who.int/csr/disease/zika/en/
– No new digest announcements identified.

WHO & Regional Offices [to 9 Feb 2019]

8 February 2019 | News release
WHO supports five countries to fight lassa fever outbreaks

6 February 2019 | Story
House by house, telling girls and families the dangers of female circumcision in Kenya

4 February 2019 | News release
Gaza patients’ painful journey to cancer treatment

 
::::::
 

Weekly Epidemiological Record, 8 February 2019, vol. 94, 06 (pp. 65–80)
:: Circulating vaccine-derived poliovirus type 1 and outbreak response in Papua New Guinea, 2018
:: Proceedings of the 2018 annual meeting of partners to Eliminate Yellow Fever Epidemics (EYE), Dakar, Senegal
:: Monthly report on dracunculiasis cases, January- December 2018

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO supports five countries to fight lassa fever outbreaks  08 February 2019
Ebola – Rwanda completes the revision of its National Contingency Plan  06 February 2019
South Sudan strengthens the country’s capacity to detect, investigate and respond seasonal and pandemic Influenza  04 February 2019

WHO Region of the Americas PAHO
:: Costa Rican Minister of Heath outlines priority areas for collaboration in visit to PAHO headquarters (02/05/2019)

WHO South-East Asia Region SEARO
– No new digest announcements identified.

WHO European Region EURO
:: Measles in Europe: record number of both sick and immunized 07-02-2019
:: Social science training enhances community engagement in health emergencies in 11 countries of the European Region 06-02-2019
:: Keep antibiotics working – limit their use this flu season 05-02-2019
:: What you need to know about digital health systems 05-02-2019

WHO Eastern Mediterranean Region EMRO
:: Gaza patients’ painful journey to cancer treatment  4 February 2019
:: Cancer patients face ‘death sentence’ in Yemen  4 February 2019

WHO Western Pacific Region
– No new digest announcements identified.
 

CDC/ACIP [to 9 Feb 2019]

http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News
CDC Media Statement from Dr. Redfield on Ending the HIV Epidemic: A Plan for America
Wednesday, February 6, 2019
“I’m excited that CDC is part of this unprecedented opportunity to end the HIV epidemic in America. The Administration’s plan will deploy the people and key prevention and treatment strategies needed to reduce new HIV infections by 75 percent over the next 5 years, with the hope of a 90 percent reduction within 10 years.

We have the tools to end new HIV infections in this Nation, but they must be applied now. The most recent data suggest that progress in reducing new infections has plateaued, and many communities remain vulnerable to HIV infection. Under this proposed initiative, we will focus on four key strategies to meet the needs of communities with the highest HIV burden: diagnose new HIV infections; treat those with infection rapidly and effectively; protect people from being infected through access to comprehensive prevention and treatment, including medications that can prevent infection; and respond quickly to and stop new outbreaks. To accomplish this, we will accelerate our work with state and local health departments. We will establish HIV elimination teams—for ‘boots-on-the-ground’ support—to ensure communities with the greatest burden make progress. We will listen to people living with HIV, and to public health partners in the most-affected communities, so we reach those in greatest need.

CDC is proud to have been part of the fight to prevent HIV from the very beginning, and we are honored to continue to work with our HHS colleagues on this important initiative. I thank the President and Secretary Azar for their visionary leadership in seizing this opportunity. The time to end the HIV epidemic is now. I have always believed in seeing the possible. Embracing the possible, we will do it together.”
–Robert R. Redfield, MD, Director, Centers for Disease Control and Prevention

MMWR News Synopsis for February 08, 2019
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2019
The child/adolescent and adult immunization schedules help health care professionals identify which vaccines their patients need, when they need them, and how many doses of each vaccine they need based on age, health conditions, and other factors. The design of the 2019 Child and Adolescent Immunization Schedule has been updated. Content updates include new or revised ACIP recommendations for hepatitis A vaccine (HepA); hepatitis B vaccine (Hep B); influenza vaccine; tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap); and clarification of recommendations for inactivated poliovirus vaccines (IPV).

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2019
The child and adolescent and adult immunization schedules help health care professionals identify which vaccines their patients need; when they need them; and how many doses of each vaccine they need based on age, health conditions, and other factors. Each year, CDC and partner organizations publish an updated schedule of immunizations recommended for every child, adolescent, and adult in the U.S. The design of the 2019 schedule has been updated. Updates to the 2019 Adult Immunization Schedule include new or revised Advisory Committee on Immunization Practices (ACIP) recommendations for influenza, hepatitis B, and hepatitis A vaccinations.

Africa CDC   [to 9 Feb 2019]

https://au.int/en/africacdc
No new digest content identified.